A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|DRUG: Nab-Paclitaxel|DRUG: Placebo
Sponsor: Hoffmann-La Roche